ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL

NCT02141451 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Non-Hodgkin Lymphoma

Interventions

DRUG: Rituximab
DRUG: INCB7839

Sponsor

Masonic Cancer Center, University of Minnesota